Krystal Biotech, Inc. (KRYS)

NMS – Цена в реальном времени. Валюта: USD

372.25

+12.32 (3.42%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

371.50

-0.75 (-0.20%)

После закрытия: Jun 26, 2026, 7:37 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Krystal Biotech, Inc. (KRYS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Krystal Biotech, Inc. (KRYS)

Is the Options Market Predicting a Spike in Krystal Biotech Stock?

Krystal Biotech Stock Soars 16% in Three Months: Here's Why

Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Пресс-релизы

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Search stocks

Krystal Biotech, Inc. (KRYS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Krystal Biotech, Inc. (KRYS)

Is the Options Market Predicting a Spike in Krystal Biotech Stock?

Krystal Biotech Stock Soars 16% in Three Months: Here's Why

Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Пресс-релизы

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference